Palvella Therapeutics Gets US Patent Supporting QTORIN Pitavastatin Through 2043
Palvella Therapeutics (PVLA) said Wednesday the United States Patent and Trademark Office has issued a patent, exclusively licensed from Yale University, supporting Palvella's QTORIN pitavastatin program for porokeratosis, including disseminated superficial actinic porokeratosis.QTORIN pitavastatin is an investigational topical therapy designed to enable pathogenesis-directed inhibition of the mevalonate pathway on-target and directly within affected skin tissue in porokeratosis, according to the company.The patent covers topical administration of HMG-CoA reductase inhibitors, including pitavastatin, for the treatment of porokeratosis, providing protection into 2043 for this pathogenesis-directed treatment approach, the company said.Palvella said it has also filed an additional patent application covering the QTORIN-derived formulation of pitavastatin and other statins and methods of use.Price: $116.72, Change: $-0.88, Percent Change: -0.74%
